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Abstract – Fumagilin-B® is the only currently registered chemical treatment available to combat nosema disease in
apiculture. Fumagillol, the basic hydrolysis product of fumagillin, two semisynthetic fumagillin analogues, and four
in-house purely synthetic compounds which were designed to mimic the mode of action of fumagillin against the
methionine aminopeptidase type 2 (MetAP-2) enzyme, was observed to exhibit statistically significant biological
activity against Nosema ceranae -infected caged bees. None of these compounds were, however, as effective as
Fumagilin-B®. The commercially available thymol and enilconazole also exhibited activity againstN. ceranae , with
thymol being the most promising chemical treatment other than Fumagilin-B®. High cumulative bee mortality was
associated with the therapeutic dosage of Fumagilin-B® during our study, suggesting the need for continued
investigation.
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1. INTRODUCTION
Nosema disease of honeybees, Apis mellifera
L., is caused by infection from two distinct species
of single-cellular microsporidian fungal parasites,
Nosema apis (Zander 1909) andNosema ceranae
(Fries et al. 1996). Infections of N. ceranae have
been shown to cause high levels of colony loss in
some regions, while both species have been im-
plicated as part of the pathogen complex associ-
ated with the colony collapse disorder (CCD)
phenomenon (Cox-Foster et al. 2007; Martín-
Hernández et al. 2007; Higes et al. 2008, 2009;
vanEngelsdorp et al. 2009). Fumagilin-B® is the
only currently available registered chemotherapy
available to treat nosema disease in North America
(Williams et al. 2011) and is reportedly allowed for
use in special circumstances in Spain, the Balkans,
and other parts of Europe (Stevanović et al. 2013).
The commercial products (Fumagilin-B® and
Fumidil-B®) both contain the therapeutic
fumagillin as the dicyclohexylamine (DCH) salt.
This results in both compounds (fumagillin and
DCH) being administered in equimolar quantities
when using either of the commercial formulations.
DCH is reportedly five times as toxic to mice as
fumagillin, and the reader is referred to a recent
review where the relative toxicities of these two
compounds are discussed in greater detail (van den
Heever et al. 2014). Fumagilin-B® (and the
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equivalent Fumidil-B®) has been continuously
employed to treat both N. apis and N. ceranae
ever since the discovery (Hanson and Eble 1949)
of fumagillin, when it was found to be effective in
controlling N. apis infections in honeybees
(Katznelson and Jamieson 1952; Bailey 1953).
Fumagillin and its analogues inhibit the forma-
tion of new blood vessels around tumors (angio-
genesis), thereby limiting the blood supply to
tumors and thus impeding their growth (Ingber
et al. 1990). Fumagillin covalently binds to a
histidine moiety (His231) within the enzymatic
active site of the methionine aminopeptidase type
2 (MetAP-2) enzyme (Griffith et al. 1997; Sin
et al. 1997; Liu et al. 1998; Zhang et al. 2002).
resulting in the irreversible opening of the spiro-
epoxide group on the core cyclohexane skeleton
of fumagillin. This spiro-epoxide is reportedly
responsible for the biological activity of
fumagillin, since opening of the epoxide by ther-
mal decomposition leads to the loss of biological
activity (Griffith et al. 1997, 1998; Kochansky
and Nasr 2004).
MetAP-2 enzymes are ubiquitous in eukaryotic
organisms, including the host honeybee and the
disease-causative N. apis and N. ceranae (Zhang
et al. 2002; Huang et al. 2013). Comparison of the
MetAP-2 enzyme binding site amino acid se-
quences among humans and A. mellifera shows
identical protein sequences, while sequences dif-
fer by only two amino acids when comparing
N. apis and N. ceranae (Huang et al. 2013).
Numerous research efforts have been aimed at
modulating the mode of action of fumagillin by
synthesizing analogues that replace the alkene
side chain (Han et al. 2000; Baldwin et al. 2002;
Chen et al. 2009; Balthaser et al. 2011) in attempts
to reduce the cytotoxicity of fumagillin while
retaining its beneficial properties. The alkene side
chain can be removed by basic hydrolysis, yield-
ing the alcohol, fumagillol (Tarbell et al. 1961;
Gochnauer and Furgala 1962; Assil and Sporns
1991). Chemical moieties such as carboxylic
acids can then be coupled to fumagillol, resulting
in new semisynthetic fumagillin analogues.
We postulated that the known mode of action
of fumagillin against the MetAP-2 enzyme in
humans is similar for MetAP-2 enzymes found
in N. apis and in N. ceranae . As such, the core
cyclohexane skeleton of fumagillin with the intact
spiro-epoxide was used as a template for the de-
sign and synthesis of several semisynthetic com-
pounds and synthetic compounds aimed at
targeting the MetAP-2 enzyme in N. ceranae .
These compounds, as well as other commercially
available chemicals that reportedly exhibited ac-
tivity against nosema disease, were evaluated for
disease suppression and adult bee survival using
cage trial assays.
2. MATERIALS AND METHODS
2.1. Reagents and materials
Trimethylsulfoxonium iodide (catalog no. T80500),
N ,N ′-dicyclohexylcarbodiimide (catalog no. D80002),
4-(dimethylamino) pyridine (catalog no. 107700), ace-
tyl salicylic acid (catalog no. A5376), piperonylic acid
(catalog no. P49805), thymol (catalog no. T0501),
carbendazim (catalog no. 378674), toltrazuril (catalog
no. 34000), thiabendazole (catalog no. T8904), and
enilconazole (also known as imazalil or chloramizole,
catalog no. Y0000136) were all purchased from Sigma-
Aldrich (St. Louis, MO, USA). Nozevit solution, a
natural plant polyphenol extract, was obtained from
Complete Bee (AK, USA). Fumagilin-B® was obtained
from Medivet Pharmaceuticals Ltd. (High River, AB,
Canada).
2.2. General synthetic methodology
Fumagillol was prepared by basic hydrolysis of
Fumagilin-B® (Figure 1) according to Assil and Sporns
(1991). Oxidation of alcohols to their corresponding
ketone compounds was performed using established
methodology (Dess and Martin 1991). The esterifica-
tion of alcohols with carboxylic acids (Figure 2), as well
as epoxidation of ketones (Figure 3), is described below.
The identity of all the synthesized compounds was
verified by high-resolution mass spectrometry on an
Agilent 6224 time of flight (TOF) mass spectrometer
(Table I).
2.2.1. Ester synthesis
The Steglich esterification (Figure 2) was used to
prepare esters from the corresponding carboxylic
acids and alcohols (Neises and Steglich 1978). The
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general procedure involved stirring a solution of the
carboxylic acid (10 mmol) in anhydrous CH2Cl2
(10 mL). The catalyst, dimethylaminopyridine
(DMAP), was added (5 mmol), followed by drop-
wise addition of the alcohol (11 mmol, 1.1 equiva-
lent). The mixture was then cooled to 0 °C, followed
by slow addition of dicyclohexylcarbodiimide
(DCC; 11 mmol, 1.1 equivalent). The mixture was
stirred for 5 min at 0 °C and then for 3 h at room
temperature. The precipitated dicyclohexyl urea
(DCU) by-product was then filtered off, and the
filtrate was washed successively with 0.5 N HCl
(2×10 mL) and saturated NaHCO3 solution
(1×20 mL). The CH2Cl2 fraction was dried (MgSO4),
concentrated in vacuo, and purified by flash chroma-
tography on silica (230–400 mesh) using a suitable
ratio of n -hexane and ethyl acetate as eluant.
2.2.2. Epoxide formation from ketones
A modified version of the Corey-Chaykovsky reac-
tion was used to prepare epoxides from ketone com-
pounds (Corey and Chaykovsky 1965; Ng 1990). shown
in Figure 3. The procedure involved dissolving
trimethylsulfoxonium iodide (10 mmol) into
dimethylsulfoxide (15 mL) under a nitrogen atmosphere
at room temperature. After stirring for 5 min, the ketone
(10mmol) was added, followed by addition of potassium
tert-butoxide (10 mmol), dissolved in dimethylsulfoxide
(10 mL). Stirring continued overnight at room tempera-
ture, followed by dilution with water (30 mL), extraction
with CH2Cl2 (3×30 mL), and in vacuo concentration.
Purification by flash chromatography on silica (230–400
mesh) using a suitable ratio of n -hexane and ethyl acetate
afforded the pure epoxide.
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Figure 1. The commercial Fumagilin-B®, consisting of fumagillin (a ) as the dicyclohexylamine (b ) salt, which can
be hydrolyzed to afford the alcohol, fumagillol (c ).
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Figure 2. Coupling of fumagillol (c ) with aspirin (d ) or piperonilic acid (f ), respectively, under Steglich reaction
conditions using N ,N ′-dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine (DMAP), to afford the aspirin
analogue (e ) and piperonilic acid analogue (g ) of fumagillin.
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2.3. Cage assays—general procedures
Frames of sealed brood with newly eclosing bees
(A. mellifera ) were obtained from several colonies at
Agriculture and Agri-Food Canada’s Research Farm, in
Beaverlodge, Alberta, Canada (55° 18′ N, 119° 17′W).
Colonies were repeatedly tested to be free from both
N. apis and N. ceranae , using both light microscopic
and molecular methods, described below. Frames were
kept overnight in an incubator (Percival Model
136NLC9, Percival Scientific Inc., Perry, IA, USA)
maintained at hive temperature (33±0.5 °C) and relative
humidity (70±5 %). Adult workers were pooled and
mixed from all frames, with 100 bees being added to
wooden screened cages (8.0×9.5×12.0 cm I.D.) for
testing. Bees were then fed 4 mL of a 60 % (w /v ) of
aqueous sucrose syrup for 24 h, using gravity feeders
fashioned from disposable centrifuge tubes (catalog no.
93000-020, VWR International, Radnor, PA, USA).
After the initial 24-h period, each cage was mass
inoculated with 5 mL of 60 % syrup solution containing
1×107 freshly harvested N. ceranae spores, prepared
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Figure 3. Purely synthetic compounds prepared by using the Corey-Chaykovsky epoxidation reaction to afford the
cyclohexanone derivative (h ), menthol derivative (i ), and other synthetic analogues (j , k , l , m , n ).
Table I. Confirmation of the identity of semisynthetic and synthetic compounds that were tested against N. ceranae
by high-resolution mass spectrometry analysis.
Compound Found formula Ion Mass found Mass calculated Δ ppm
c C16H24O3Na [M + Na (−H2O)]+ 287.1631 287.1618 4.65
e C25H32O7Na [M + Na]
+ 467.2033 467.2040 −1.49
g C24H28O6K [M + K (−H2O)]+ 451.1512 451.1517 −1.23
h C7H12ONa [M + Na]
+ 135.0776 135.0780 −3.49
i C11H21O [M + H]
+ 169.1592 169.1587 2.72
j C9H13O2 [M + H (−H2O)]+ 153.0913 153.0910 1.96
k C10H20NO [M + NH4]
+ 170.1531 170.1539 −4.72
l C9H15O3 [M + H]
+ 171.1024 171.1016 4.96
m C11H20O2Na [M + Na]
+ 207.1351 207.1356 −2.02
n C25H33O7 [M + H]
+ 445.2234 445.2221 3.00
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from previously identified colonies of honeybees with
high levels of N. ceranae infection. Workers from
infected colonies were euthanized on dry ice; their
abdomens were then removed and suspended in ultra-
pure water (1 mL per bee). After maceration, the crude
suspension was filtered through a sieve (∼0.8 mm), with
spores counted according to procedures below. Suitable
dilution yielded the inoculum in 60 % sucrose syrup,
which was fed for 48 h to the prepared cages of bees,
during which time, all the inoculum was consumed.
Although mass inoculation may introduce more vari-
ability with respect to individual bee infection levels
than individual bee inoculation, this method is an ac-
ceptable and efficient approach to screen a large number
of compounds over several concentrations and repli-
cates (Fries et al. 2013). We have found an inoculum
spore concentration of 1×107 to be an effective discrim-
inatory spore dose during previous cage trial work. It
also exceeds the IC100 level for N. ceranae , and it also
falls into the range of infection doses used in several
other studies. Based on our previous work, day 17 has
also been established as the day where we observed
maximum infectivity. Test compounds were subse-
quently fed to bees in 60 % sucrose solution ad libitum
for 17 days, at prescribed dosages.
Five or six replicate cages of bees were evaluated for
each concentration of each compound tested. The effi-
cacy of test compounds for suppressing N. ceranae
spore development was assessed by determining the
average number of spores per bee at 17 days post-
inoculation. Cumulative bee mortality per cage over
the duration of the trials was also calculated as the
sum of daily bee deaths on day 17, expressed as a
proportion of the initial starting population; all bees
remaining on day 17 were removed for spore analysis.
2.3 .1 . Determination of spore levels
and Nosema spp. identification
To determine Nosema infection levels in colonies,
60 adult workers were collected from peripheral frames
of the brood nest, and for cage trials, 30 surviving
workers were removed from each cage 17 days post-
inoculation. Bees were euthanized and had their abdo-
mens placed into a stomacher bag containing 70 %
ethanol (1 mL per bee). The abdomens were then mac-
erated for 1 min at medium speed (Seward Stomacher®
80 Biomaster, Seward Laboratory Systems Inc., Davie,
FL, USA), and 6μL of the macerate was withdrawn and
loaded onto a Helber Z30000 counting chamber
(Hawksley, Lancing, UK), with spores counted accord-
ing to the generalized methods of Cantwell (1970)
under phase contrast microscopy at 400×magnification.
Samples of the remaining crude macerate were por-
tioned into 1.5-mL microcentrifuge tubes and stored at
−20 °C.
For Nosema spp. identification, the crude frozen
macerate was thawed and vortexed, and then, 200–
400 μL was centrifuged to remove the ethanol from
the sample. DNA extraction was performed using the
DNeasy® Blood & Tissue Kit (Qiagen®, Valencia, CA,
USA). The concentration of the extracted DNA was
determined spectrophotometrically (NanoDrop 2000C,
Thermo Scientific, West Palm Beach, FL, USA),
whereafter 50–100 ng of this DNA extract was ampli-
fied using polymerase chain reactions (PCRs).
A multiplex system that co-amplified the 16S rRNA
gene of N. apis and N. ceranae (Martín-Hernández
et al. 2007) as well as the honeybee ribosomal protein
RpS5 gene (Thompson et al. 2007) was used within the
same reaction. All PCR reactions were performed using
a Mastercycler® proS thermocycler (Eppendorf, Missis-
sauga, Canada) and utilizing the Illustra™ PuReTaq
Ready-To-Go™ PCR beads (GE Healthcare Life Sci-
ences, Baie d’Urfe, Quebec, Canada). PCR beads were
reconstituted to a 25 μL final volume by adding sterile
H2O, 0.5 μL of 20-mM forward and reverse primers (a
final concentration of 0.4 mM), and the DNA. All PCR
products were visualized on a 2 % agarose gel and
stained with SYBR® Safe DNA gel stain (Life Technol-
ogies, Carlsbad, CA, USA).
2.3.2. Testing of semisynthetic, synthetic,
and commercially available compounds
In 2010, Fumagilin-B® was used to prepare three
positive control solutions at concentrations of 4, 40,
and 400 μM Fumagilin-B® in 60 % sucrose solution,
by first dissolving the appropriate amount of Fumagilin-
B® into 1.0 mL ethanol, before adding it to the 60 %
sucrose solution. Concentration ranges were chosen to
encompass the manufacturer’s recommended dose con-
centration of 41 μM (105 mg fumagillin DCH salt,
corresponding to 5 g of the formulation, dissolved into
4 L of sucrose syrup). The aspirin and piperonyl ana-
logues of fumagillin (Figure 2, compounds e and g ), as
well as fumagillol (Figure 1, compound c ) and the
commercially available carbendazim, thiabendazole,
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and thymol (Figure 4, compounds o , q , and r ), were
also prepared and tested at concentrations of 4, 40, and
400 μM. A negative control consisted of only 60 %
sucrose with 1 mL of added ethanol. Nozevit, sold as a
bee supplement consisting of a mixture of unspecified
polyphenols and other compounds, was prepared and
tested as per the manufacturer’s instructions. Several
synthetic compounds (Figure 3, compounds h , i , j ,
and k ) were also similarly prepared and tested.
In 2011, only a single positive control sample of
Fumagilin-B® was prepared at 40 μM, along with the
previously described negative control. This was done
since Fumagilin-B® almost completely eliminated
N. ceranae spores in honeybees at a concentration of
40 μM during the 2010 trials and due to the fact that we
observed a significant increase in bee mortality at higher
concentrations of Fumagilin-B® (Table IV). Screening of
synthetic compounds at concentrations greater than
40 μM in 2011 was done in order to facilitate detection
of potential biological activity, given the possibility that
test compounds may not be as biologically active as
Fumagilin-B®. Thus, the test concentrations of synthetic
compounds in 2011 (and subsequent years) were in-
creased to 40, 400, and 800 μM. The semisynthetic
aspirin analogue (Figure 2, compound e ) as well as the
commercially available toltrazuril and carbendazim (Fig-
ure 4, compounds p and o ) were also tested during 2011.
In 2012, testing was conducted using the same 40,
400, and 800 μM concentration regimen as described
above for the 2011 tests. Three synthetic compounds
(Figure 3, compounds l , m , and n ), as well as the
commercially available enilconazole (Figure 4, com-
pound s ) and aspirin by itself (Figure 2, compound
d ), was tested.
2.4. Statistical analysis
The effectiveness of compounds was evaluated by
using regression models of spore counts that included
compound dose as the explanatory variable. Indicators
for each dose were included, compared to 0-μM nega-
tive controls as the referent, because the relationship
between dose and spore count was not linear. Separate
negative binomial (NB) or zero-inflated negative bino-
mial (ZINB) regression models were run for each com-
pound. Models were selected using the following
criteria (Dohoo et al. 2009). (1) Linear regression
models for spore count violated residual assumptions
and were not used, despite a log transformation of spore
count. (2) NBmodels were selected as the mean number
of spore counts were not equal to the variance of
Poisson models for count data (the overdispersion pa-
rameter of NB models was significantly different than
0). (3) ZINBmodels were selected when the Vuong test
was significant (P≤0.05), indicating that there may be a
separate process involved for those bees with zero spore
counts. (4) For the inflated (logistic) portion of ZINB
models, Akaike’s and Bayesian information criteria
(AIC and BIC) were used to determine the best fit for
compound dose (dose indicators compared to treated
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Figure 4. Commercially available compounds evaluated included carbendazim (o ), toltrazuril (p ), thiabendzole
(q ), thymol (r ), and enilconazole (s ). Nozevit, another commercially available product tested, is a bee supplement
consisting of a mixture of unspecified polyphenols and other compounds.
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versus non-treated, lower AIC and BIC representing a
better fitting model).
Likelihood ratio tests (LRTs) were used to deter-
mine if groups of concentration indicators were sig-
nificantly associated with changes in spore count
(P ≤0.05). If the LRT was significant, Wald tests
were used to compare each individual dose to the
referent concentration (0 μM). The fit of NB models
Table II. Results of the negative binomial models to assess the relationship between test compound concentration
and average N. ceranae spore count at 17 days post-infection after feeding each compound ad libitum in 60% sugar
solution.
Compound Numbera Dose
(μM)b
IRRc LRT P
valued
Wald P
valuee
95 % confidence
intervalf
Cyclohexanone
derivative (h )
28 0 Referent 0.03 – –
– 6 4 0.35 – 0.02 0.14–0.87
– 6 40 0.41 – 0.06 0.16–1.03
– 6 400 0.32 – 0.02 0.13–0.81
Compound( j ) 28 0 Referent 0.03 – –
– 6 4 0.24 – 0.01 0.08–0.73
– 6 40 0.21 – 0.01 0.07–0.63
– 6 400 0.44 – 0.15 0.15–1.35
Compound (k ) 28 0 Referent <0.01 – –
– 6 4 0.55 – 0.22 0.21–1.43
– 6 40 0.08 – <0.01 0.03–0.21
– 6 400 0.43 – 0.09 0.17–1.13
Compound (n ) 28 0 Referent <0.01 – –
– 5 40 2.56 – 0.07 0.93–7.04
– 5 400 3.49 – 0.02 1.27–9.60
– 4 800 5.64 – <0.01 1.85–17.20
Aspirin (d ) 43g – Dose 0.52 – –
Compound (i ) 46g – Dose 0.07 – –
Compound (l ) 46g – Dose 0.44 – –
Compound (m ) 46g – Dose 0.85 – –
Carbendazim (o ) 63g – Dose 0.67 – –
Toltrazuril (p ) 47g – Dose 0.09 – –
Thiabendazole (q ) 46g – Dose 0.12 – –
Nozevit 46g – Dose 0.32 – –
a Total number of cages of 100 bees for each dose. Spore counts for each cage represent the average number of spores per bee
b The dose of each compound tested compared to negative controls (0 μM)
c Incident rate ratio (ratio of spore counts per bee of the dose in question compared to the referent negative control dose). IRRs are
not shown for compounds where the dose variable was not significantly associated with changes in spore counts (see e)
d Likelihood ratio test of whether or not the group of indicators for dose is significant to the model for spore count
eWald tests of whether or not IRR for each individual dose compared to controls is significantly different than 1.0
f The 95 % confidence interval for the IRR
g These numbers also include 28 cages of controls
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was assessed using deviance chi-squared tests
(P ≤0.05 indicating that the model did not fit the
data) and residual analysis. The fit of ZINB models
was assessed by residual analysis.
Differences in mortality for compounds significantly
related to spore count were evaluated descriptively by
comparing proportions of mortality for bees in all repli-
cates of a given dose compared to controls.
All analyses were conducted in Excel 2010
(Microsoft Corporation, Redmond, WA, USA) and
STATA Intercooled 13.1 (StataCorp LP, College Sta-
tion, TX, USA).
Table IV. Cumulative mortalities for bees infected with N. ceranae that were fed varying concentrations of test
compounds ad libitum in 60 % sugar solution.
Treatment Dose (μM) Dead Total Mortality (%) Mean spore count (×106)
Control 0 1587 2810 56.5 7.21
Fumagilin-B® 4 634 1100 57.6 4.07
40 1634 2300 71.0 0.42
400 939 1100 85.4 0.02
Fumagillol (c ) 4 226 600 37.7 2.92
40 413 600 68.8 1.00
400 541 600 90.2 0.35
Aspirin analogue (e ) 4 304 600 50.7 3.46
40 267 600 44.5 2.17
400 1084 1900 57.1 1.32
800 441 600 73.5 0.75
Piperonyl analogue (g ) 4 288 600 48.0 1.63
40 276 600 46.0 1.75
400 416 600 69.3 2.17
Compound (h ) 4 280 600 46.7 2.50
40 267 600 44.5 2.96
400 332 600 55.3 2.33
Compound (j ) 4 302 600 50.3 1.75
40 351 600 58.5 1.50
400 217 600 36.2 3.21
Compound (k ) 4 264 600 44.0 3.96
40 332 600 55.3 0.58
400 320 600 53.3 3.13
Compound (n ) 40 182 500 36.4 18.50
400 427 500 85.4 25.20
800 494 500 98.8 40.70
Thymol (r ) 4 268 600 44.7 1.58
40 276 600 46.0 5.38
400 308 600 51.3 2.54
Eniconazole (s ) 40 355 500 71.0 4.95
400 340 500 68.0 10.80
800 493 500 98.6 2.42
Only compounds that had a statistically significant impact on spore counts are included. One cage contained 110 rather than 100
bees
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3. RESULTS
Molecular identification confirmed that only
N. ceranae was present in the inoculum used to
infect our caged bees, with no N. apis being
detected.
The results of the NB and ZINB models are
shown in Tables II and III, respectively.
Fumagilin-B®, as well as fumagillol (Figure 1,
compound c ), exhibited statistically significant
biological activity against N. ceranae under our
test conditions (Table III). Both the semisynthetic
aspirin (Figure 2, compound e ) and piperonyl
analogues (Figure 2, compound g ) showed statis-
tically significant biological activity against
N. ceranae -infected bees as well. From Tables II
and III, it can be seen that four purely synthetic
compounds (Figure 3, compounds h , j , k , and
n ), as well as the commercially available thymol
and enilconazole (Figure 4, compounds r and s ),
also showed statistically significant biological ac-
tivity against N. ceranae . Thymol lowered the
N. ceranae spore count by an average of 40 %
over all three test concentrations after 17 days,
when compared to the control group (Table IV).
The commercial formulation (Fumagilin-B®) was
the only treatment in this study that was effective
in eliminating N. ceranae spores in caged
honeybees.
Cumulative bee mortalities by concentrations
for those compounds shown to significantly im-
pact spore count are shown in Table IV. It is
interesting to note the higher bee mortality asso-
ciated with Fumagilin-B®, when compared to the
negative control. The mortality associated with
Fumagilin-B® also increased with an increase in
concentration.
4. DISCUSSION
All of the semisynthetic and pure synthetic
compounds tested were chosen for ease of prep-
aration using readily available starting mate-
rials that were preferentially naturally occurring
compounds possessing antifungal properties.
Starting materials were also selected to contain
either an alcohol or ketone functional group,
located on a cyclohexane moiety, which mimics
the core structure of fumagillin. The alcohols
and ketones were converted into epoxides,
using the described methodologies. Both semi-
synthetic derivatives of fumagillol (Figure 1,
compound c ) , namely, the aspir in and
piperonylic acid analogues (Figure 2, com-
pounds e and g ), were observed to exhibit statis-
tically significant, although lower, activity against
N. ceranae -infected bees in cage trial assays when
compared with the Fumagilin-B® positive control
(Table III). Fumagillol itself also exhibited statisti-
cally significant but lower biological activity than
Fumagilin-B® (Table III), which is consistent with
reports citing lower biological activity of the alco-
hol (Gochnauer and Furgala 1962). Although the
aspirin analogue (Figure 2, compound e ) was ob-
served to be biologically active againstN. ceranae ,
aspirin by itself did not exhibit any statistically
significant activity against N. ceranae -infected
bees (Table II), even though it does possess anti-
fungal properties.
Four of the purely synthetic compounds (Fig-
ure 3, compounds h , j , k , and n ) were also
observed to exhibit statistically significant activity
against N. ceranae , though inferior to that of
Fumagilin-B® (Tables II and III). One of these
compounds was the simple cyclohexanone deriv-
ative (Figure 3, compound h ), which was previ-
ously synthesized and tested for activity against
the MetAP-2 enzyme, with only trace amounts of
biological activity being observed (Arico-
Muendel et al. 2009). Of the six commercially
available compounds (including Nozevit) tested
(Figure 4, compounds o , p , q , r , and s ), only
thymol and enilconazole (Figure 4, compounds r
and s ) were observed to be biologically active
against N. ceranae (Table III). Thymol lowered
the N. ceranae spore count by an average of 40 %
over all three test concentrations after 17 days,
when compared to the control group. Similar ben-
eficial effects were previously described for thy-
mol, where N. ceranae -infected bees treated with
0.12 mg g−1 thymol in candy (85 % icing sugar,
10 % honey, 5 % water, and 3.2 μL g−1 ethanol)
were reported to have only 8.8 % of the amount of
spores after 25 days, when compared to a control
group (Maistrello et al. 2008). Thymol, when fed
to N. ceranae- infected bees in a 0.1 mg g−1 con-
centration in either a 50 % (w /v ) sugar syrup or in
a candy form (85 % icing sugar, 10 % honey, 5 %
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water, and 3.2 μL g−1 ethanol), reduced the
N. ceranae spore counts by 50 % after 25 days
when compared to a control group (Costa et al.
2010). while the life span of thymol-treated bees
also increased by 3 days. Thymol is registered in
Canada under the trade name of Thymovar™ (reg-
istration no. 29747) and is sold as cellulose-
impregnated thymol fumigant for use against
Varroa destructor (Anderson and Trueman
2000) infestations. In the EU and the USA, thy-
mol is sold as a fumigant gel (Apiguard®), or as a
combination with menthol, camphor, and euca-
lyptol, as an impregnated wafer (Apilife Var®). It
would be interesting to establish whether thymol
applied as a fumigant may be providing some
secondary protection against nosema disease,
compared to it being applied orally.
A recent study on the naturally occurring
ligerin (Figure 5, compound u ) found that it was
equally or more active against osteosarcoma cell
lines than fumagillin. Ligerin is structurally very
similar to fumagillin, except for the shortened side
chain and the replacement of the spiro-epoxide by
a chlorohydrin moiety. This is interesting, since
the spiro-epoxide on the cyclohexane skeleton of
ligerin is opened (Blanchet et al. 2014). which
should result in the loss of biological activity
(Assil and Sporns 1991). Conversion of
fumagillin, as well as and the other synthetic
biologically active compounds observed in our
study, to chlorohydrin compounds could perhaps
result in increased biological activity against
N. ceranae .
However, a major complication in developing
new fumagillin analogues for apicultural usage
based on their mode of action against the
MetAP-2 enzyme is still the presumably low se-
lectivity of fumagillin and other analogues be-
tween the host honeybee and N. ceranae
MetAP-2 enzyme (Huang et al. 2013). Further
research into the identification of other enzymes
that may be present in N. ceranae is desirable.
This might lead to the discovery of enzymes that
may be crucial for the proliferation of the Nosema
spp., while ideally not affecting the host honey-
bee. If such enzymes could be identified, it could
afford different biological targets which could be
pursued in future chemotherapy research.
The increased mortality associated with
Fumagilin-B® usage requires further investiga-
tion, as Fumagilin-B® contains not only
fumagillin but also the reportedly genotoxic and
tumorigenic DCH. The effect of DCH on bee
mortality is examined in a succeeding study (van
den Heever et al. 2015).
5. CONCLUSIONS
Four purely synthetic compounds prepared for
this study were found to exhibit statistically sig-
nificant biological activity against N. ceranae ,
although none were as effective as Fumagilin-
B®. Fumagillol and the semisynthetic aspirin and
piperonyl fumagillin analogues also exhibited sta-
tistically significant activity against N. ceranae ,
but again, none of these were as effective as
O
O
OMe
O
O
OH
O
O
O
OMe
O
O
OHO
OH
O
OMe
O
OH
O
a ut
O
Cl
Figure 5. Comparison of the chemical structures of the biologically active fumagillin (a ), UV-decomposed
fumagillin diastereomeric compounds (t ), and the naturally occurring chlorohydrin, ligerin (u ), which is reportedly
equally or more biologically active against osteosarcoma cell lines than fumagillin, in spite of the fact that the intact
spiro-epoxide (which is reportedly responsible for biological activity of fumagillin analogues) is not present in this
compound.
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Fumagilin-B®. Among the commercially available
compounds evaluated, only thymol and
enilconazole were found to exhibit activity against
N. ceranae . The high bee mortality related to
enilconazole usage makes this compound less at-
tractive for commercial purposes; however, thymol
is a commercially available product that might be
more useful in controlling nosema disease.
Although no resistance to Fumagilin-B® has
been reported in apiculture for either N. apis or
N. ceranae , there has been a report of resistance
being observed to the usage of Fumidil-B® for an
unidentified Nosema spp. infecting the diamond-
back moth, Pluetella xylostella L. (Idris et al.
2001). Based on this report, it could be speculated
that resistance to fumagillin may develop in api-
culture in future, owing to the prolonged usage of
fumagillin against nosema disease, dating back
almost to its discovery in the early 1950s. Re-
search into the development of new chemical
treatments against nosema disease in apiculture
is therefore of utmost importance, given that
Fumagilin-B® is currently the only effective
chemical treatment available.
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